Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | EDNRB | P24530 | 1/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11416663 | 0.81 | MEN1 (0.36) | EDNRBEDNRAHSD17B10ALDH1A1MEN1 | |
| SCHEMBL8559782 | 0.79 | TDO2 (0.38) | CYP1A2TSHREDNRBEDNRAHSD17B10 | |
| SCHEMBL4213119 | 0.79 | MAOB (0.39) | ALDH1A1MEN1POLBKMT2AMAPT | |
| SCHEMBL21533082 | 0.78 | MEN1 (0.36) | CYP1A2TSHRALDH1A1MEN1POLB | |
| SCHEMBL11412655 | 0.74 | METAP1 (0.40) | — | |
| SCHEMBL8780449 | 0.73 | BCHE (0.38) | CYP1A2ALDH1A1MAPT | |
| SCHEMBL6474398 | 0.72 | CYP19A1 (0.44) | CYP1A2TSHRMAPT | |
| SCHEMBL6314591 | 0.72 | MEN1 (0.40) | EDNRBEDNRAHSD17B10ALDH1A1ATM | |
| SCHEMBL3649102 | 0.70 | EDNRB (0.32) | EDNRBEDNRAALDH1A1MEN1POLB | |
| SCHEMBL10670754 | 0.69 | MEN1 (0.38) | EDNRBEDNRAALDH1A1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593456-B1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | UNIV COLUMBIA (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20120270912-A1 | Substituted Indolealkanoic Acids | JONES MICHAEL LEE (US) | 2012-10-25 | — | — | US | disclosed |
| US-8163932-B2 | Substituted indolealkanoic acids | ALINEA PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120065203-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2012-03-15 | — | — | US | disclosed |
| US-20100324105-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100324039-A1 | Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100137301-A1 | Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2010-06-03 | — | — | US | disclosed |
| US-7659269-B2 | Substituted indolealkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2010-02-09 | — | — | US | disclosed |
| US-7572910-B2 | Pyridazinone aldose reductase inhibitors | PFIZER, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080214540-A1 | 3-[(phenyl or benzothiazol-2-yl)methyl]indole-N-acetic acids and esters; analgesics; aldose reductase inhibitors; diabetes complications including cataracts, retinopathy, nephropathy, and neuropathy; side effect reduction | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2008-09-04 | — | — | US | disclosed |
| EP-0322153-A2 | Heterocyclic oxophtalazinyl acetic acids | PFIZER INC. (US) | 1989-06-28 | — | — | EP | disclosed |
| EP-0322153-A2 | Heterocyclic oxophtalazinyl acetic acids | PFIZER INC. (US) | 1989-06-28 | — | — | EP | disclosed |
| EP-0313202-A2 | Process for preparing halomethyl thiazoles | PFIZER INC. (US) | 1989-04-26 | — | — | EP | disclosed |
| EP-0313202-A2 | Process for preparing halomethyl thiazoles | PFIZER INC. (US) | 1989-04-26 | — | — | EP | disclosed |
| EP-0295051-A2 | Preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains | PFIZER INC. (US) | 1988-12-14 | — | — | EP | disclosed |
| EP-0295051-A2 | Preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains | PFIZER INC. (US) | 1988-12-14 | — | — | EP | disclosed |
| EP-0295051-A2 | Preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains | PFIZER INC. (US) | 1988-12-14 | — | — | EP | disclosed |
| EP-0222576-A2 | Heterocyclic oxophthalazinyl acetic acids | PFIZER INC. (US) | 1987-05-20 | — | — | EP | disclosed |
| EP-0222576-A2 | Heterocyclic oxophthalazinyl acetic acids | PFIZER INC. (US) | 1987-05-20 | — | — | EP | disclosed |
| EP-0222576-A2 | Heterocyclic oxophthalazinyl acetic acids | PFIZER INC. (US) | 1987-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065203-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | LIPG, PNLIP, LIPA | APEX1 3026/4885CYP1A2 2720/4885TSHR 967/4885 |
| US-20100324039-A1 | Substituted Indolealkanoic Acids | GPR119, AANAT, AADAT | APEX1 3225/4885CYP1A2 1103/4885TSHR 1010/4885 |
| US-20100324105-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | LIPG, PNLIP, LIPA | APEX1 3026/4885CYP1A2 2720/4885TSHR 967/4885 |
| US-20100137301-A1 | Substituted Indolealkanoic Acids | GPR119, AANAT, AADAT | APEX1 3225/4885CYP1A2 1103/4885TSHR 1010/4885 |
| US-20120270912-A1 | Substituted Indolealkanoic Acids | GPR119, AANAT, AADAT | APEX1 3225/4885CYP1A2 1103/4885TSHR 1010/4885 |
| US-20080214540-A1 | 3-[(phenyl or benzothiazol-2-yl)methyl]indole-N-acetic acids and esters; analgesics; aldose reductase inhibitors; diabetes complications including cataracts, retinopathy, nephropathy, and neuropathy; side effect reduction | AKR1C3, AKR1C2, AKR1B1 | APEX1 3528/4885CYP1A2 319/4885TSHR 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.